The Renin-Angiotensin System medicine sales in Belgium are projected to witness consistent growth from 2024 to 2028. The sales in 2023 stood at 270 million USD PPP, and the forecasted values show a steady increase, reaching 277.8 million USD PPP by 2028. The year-on-year growth rate is modest, ranging between 0.7% and 0.4% annually. Over the last two years, this sector has shown a resilience with a consistent upward trend, and the Compound Annual Growth Rate (CAGR) over the five year period from 2024 to 2028 is approximately 0.5%.
Future trends to watch for include the impact of new regulatory policies, advancements in alternative treatments, and demographic changes such as aging population which could drive demand. Close monitoring of competitive dynamics and innovation in the sector will also be crucial in shaping future market trends.
